{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007365","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.498482+00:00","generated_at":"2026-06-18T05:10:11.414757+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncotelic publishes study showing TGF-β2 predicts poor survival in DIPG; OT-101 protocol accepted by NIHR","bullets":["Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).","TGFβ1 and TGFβ3 isoforms are also predictive; OT-101 is the only TGFβ2 inhibitor in late clinical development.","Clinical study protocol for OT-101 in pediatric brainstem cancer accepted onto UK NIHR portfolio.","CEO states targeting TGFβ2 could rectify previous clinical failures such as bintrafusp alfa."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007365","json":"https://secwatch.observer/filing/0001493152-23-007365.json","markdown":"https://secwatch.observer/filing/0001493152-23-007365.md","text":"https://secwatch.observer/filing/0001493152-23-007365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/0001493152-23-007365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:10:11.414757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}